CClinicalTrials.gg
RecruitingNCT05414357ICANSLEEPUpdated Sep 30, 2026

Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer

An interventional study of Functional Magnetic Resonance Imaging at rest and in activation with attentional task in Breast Cancer, Sleep and Quality of Life, sponsored by Centre Francois Baclesse. Recruiting at 2 sites in France. Open to female participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Centre Francois Baclesse · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
45 Years to 65 Years
Sex
Female
01

Study summary

Patients treated for breast cancer frequently complain of sleep disturbances, about 40% of them. Of the sleep disturbances experienced by patients, insomnia is the most common complaint. The prevalence of insomnia complaints is higher in breast cancer patients compared to other types of cancer, and is also higher than in the general population (between 20% and 70% in breast cancer patients vs 30% in the general population). A recent study indicates that sleep complaints concern 25% of patients even before diagnosis, and 46% (including 18% complaining of insomnia) at the time of diagnosis, showing the negative impact of the announcement of the pathology on the subjective quality of sleep, and particularly on symptoms suggestive of insomnia. However, objective information on a modification of sleep patterns in breast cancer remains scarce and does not allow us to conclude. In particular, previous studies have focused only on the effects of chemotherapy and have not always included a control group, limiting the significance of their results. The links with cognitive and psychopathological processes and the underlying mechanisms are not clearly demonstrated in this pathology. Finally, taking into account patients' complaints, it appears necessary to limit sleep disorders in breast cancer in order to improve patients' quality of life using non-medicinal and easy-to-implement approaches.

02

Conditions studied

  • Breast Cancer
  • Sleep
  • Quality of Life

Browse trials for

03

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients aged 39 to 69 years
  • A patient with localized breast cancer who has undergone surgery and may or may not be about to begin adjuvant treatment with chemotherapy or radiation therapy
  • Patient with education level 3 "end of primary education"
  • Patient with a good command of the French language
  • Patient with access to the Internet from a computer at home
  • Patient having signed the consent to participate in the study
  • Patient with no pre-existing cognitive impairment at the time of cancer diagnosis
  • Patient with a sleep complaint (ISI > 7)

Exclusion criteria

Exclusion Criteria:

  • Patient with metastatic cancer
  • A patient with a primary cancer other than breast cancer and/or a history of treated cancer
  • Patient with a history of neurological damage
  • Patient with treated sleep apnea
  • Patient with drug use or alcohol abuse (≥3 drinks/day on average and/or >10 drinks/week)
  • Patient with a treatment that has not been stabilized for at least 3 months (hypnotics, antidepressants, anxiolytics)
  • Patient with a personality disorder and/or an evolving psychiatric pathology
  • Patient with a contraindication to MRI (claustrophobia, metallic objects in the body)
  • Patient with an uncorrected vision problem
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Patients with chemotherapy or radiotherapy

    Diagnostic Test: Functional Magnetic Resonance Imaging at rest and in activation with attentional task

  • Active comparator
    cancer-free volunteers

    Diagnostic Test: Functional Magnetic Resonance Imaging at rest and in activation with attentional task

Interventions

  • Diagnostic testFunctional Magnetic Resonance Imaging at rest and in activation with attentional task

    Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include: * Functional and Anatomic Magnetic Resonance Imaging at rest and in activation (only at T1 and T2). * Biological and physiological measurements * Spatial memory task * Cognitive battery * Questionnaires (sleep, quality of life)

    Also known as: Spatial memory task, Cognitive battery, quality of life questionnaires

05

What researchers measure

Primary outcomes

  1. Ratio of total sleep time to time spent in bed and the number of awakenings lasting more than one minute measured by polysomnography with actimeter

    Time frame: At 6 months

  2. Amplitude of activity-rest rhythm measured with actimeter

    Time frame: At 6 months

  3. Acrophase of activity-rest rhythm measured with actimeter

    Time frame: At 6 months

06

Study locations

1 of 2 sites recruiting
  • Centre François Baclesse
    Caen, 14000, France
    • Carine SEGURA-DJEZZAR, MD · Contact · c.segura.djezzar@baclesse.unicancer.fr · +33 2 31 45 50 02
    • Carine SEGURA-DJEZZAR, MD · Principal investigator
    • Christelle LEVY, MD · Sub investigator
    • George EMILE, MD · Sub investigator
    • Adeline MOREL, MD · Sub investigator
    Recruiting
  • Inserm-Ephe-Unicaen U1077
    Caen, 14000, France
    • Fausto VIADER, PhD · Contact
    • Fausto VIADER, PhD · Principal investigator
    • Vincent DE LA SAYETTE, PhD · Sub investigator
    • Olivier MARTINAUD, PhD · Sub investigator
    • Pierre DENISE, PhD · Sub investigator
    Not yet recruiting
07

References and documents

Publications

  • Galin M, de Girolamo L, Clarisse B, Segura-Djezzar C, Glockner F, Elia C, Rehel S, Clochon P, Doidy F, Chavant J, Etard O, Viader F, Grellard JM, Lequesne J, Joly F, Eustache F, Martin T, Giffard B, Quarck G, Perrier J. Exploration of effects of galvanic vestibular stimulation on circadian rhythms and its associations with sleep and spatial memory in patients with breast cancer: The ICANSLEEP-2 protocol. PLoS One. 2024 Jul 31;19(7):e0306462. doi: 10.1371/journal.pone.0306462. eCollection 2024. PubMed 39083526 ↗
  • Elia C, de Girolamo L, Clarisse B, Galin M, Rehel S, Clochon P, Doidy F, Segobin S, Viader F, Naveau M, Delcroix N, Segura-Djezzar C, Grellard JM, Lequesne J, Etard O, Martin T, Quarck G, Eustache F, Joly F, Giffard B, Perrier J. Effects of sleep disturbances and circadian rhythms modifications on cognition in breast cancer women before and after adjuvant chemotherapy: the ICANSLEEP-1 protocol. BMC Cancer. 2023 Dec 1;23(1):1178. doi: 10.1186/s12885-023-11664-x. PubMed 38041077 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT05414357
Lead sponsor
Centre Francois Baclesse
Collaborators
UMR_S 1077 Inserm-EPHE-Normandie Université
Responsible party
Sponsor
First posted
Jun 10, 2022
Start date
Mar 20, 2023
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Carine SEGURA-DJEZZAR, MD
Contact
c.segura.djezzar@baclesse.unicancer.fr
+33 2 31 45 50 02

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion